Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2011

01-07-2011 | Commentary

Diabetes and cognitive performance: a story that is still unfolding

Author: A. M. Jacobson

Published in: Diabetologia | Issue 7/2011

Login to get access

Excerpt

One question voiced by patients and clinicians is whether diabetes could lead to brain damage and cognitive dysfunction. Careful systematic studies are extremely important to ascertain the nature and extent of these central nervous system complications. …
Literature
1.
Cukierman-Yaffe T, Gerstein HC, Williamson JD et al (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Trial. Diabetes Care 32:221–226PubMedCrossRef
2.
Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens PC (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64–74PubMedCrossRef
3.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842–1852CrossRef
4.
Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301:1565–1572PubMedCrossRef
5.
Zammitt NN, Frier BM (2005) Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28:2948–2961PubMedCrossRef
6.
Jacobson AM, Ryan CM, Cleary PA et al (2011) Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. Diabetologia 54:245–255PubMedCrossRef
7.
Ding J, Strachan MWJ, Reynolds RM et al (2010) Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59:2883–2889PubMedCrossRef
8.
Sanz C, Andrieu S, Sinclair A, Hanaire H, REAL.FR Study Group (2009) Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 73:1359–1366PubMedCrossRef
9.
Christman AL, Matsushita K, Gottesman RF et al. (2011) Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetologia. doi:10.​1007/​s00125-011-2095-7
10.
Rizzo M, Marfella R, Barbieri M et al (2010) Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 33:2169–2174PubMedCrossRef
11.
Young SE, Mainous AG 3rd, Carnemolla M (2006) Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 29:2688–2693PubMedCrossRef
12.
Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 9(56):42–48
13.
Wong TY, Klein R, Sharrett AR et al (2002) Atheroslerosis risk in communities study. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA 288:67–74PubMedCrossRef
14.
Knopman DS, Mosley TH, Catellier DJ, Coker LH, Atherosclerosis Risk in Communities Study Brain MRI Study (2009) Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement 5:207–214PubMedCrossRef
15.
Pavlik VN, de Moraes SA, Szklo M, Knopman DS, Mosley TH Jr, Hyman DJ (2003) Relation between cognitive function and mortality in middle-aged adults: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 157:327–334PubMedCrossRef
16.
Wong TY, Mosley TH Jr, Klein R, Klein BE, Sharrett AR, Couper DJ, Hubbard LD (2003) Atherosclerosis Risk in Communities Study. Retinal microvascular changes and MRI signs of cerebral atrophy in healthy, middle-aged people. Neurology 61:806–811PubMed
17.
Alves de Moraes S, Szklo M, Knopman D, Sato R (2002) The relationship between temporal changes in blood pressure and changes in cognitive function: Atherosclerosis Risk in Communities (ARIC) Study. Prev Med 35:258–263PubMedCrossRef
18.
Alonso A, Mosley TH Jr, Gottesman RF, Catellier D, Sharrett AR, Coresh J (2009) Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) Study. J Neurol Neurosurg Psychiatry 80:1194–1201PubMedCrossRef
19.
Lyoo IK, Yoon S, Musen G et al (2009) Altered cerebral glutamate–glutamine–γ-aminobutyric acid levels and low cognitive performance and depressive symptoms in type 1 diabetes mellitus. Arch Gen Psychiatry 66:879–887CrossRef
20.
Suzuki R, Lee K, Jing E et al (2010) Diabetes and insulin in regulation of brain cholesterol metabolism. Cell Metab 12:567–579PubMedCrossRef
21.
Musen G, Lyoo IK, Sparks CR et al (2006) Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 55:326–333PubMedCrossRef
22.
Kodl CT, Franc DT, Rao JP et al (2008) Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes 57:3083–3089PubMedCrossRef
Metadata
Title
Diabetes and cognitive performance: a story that is still unfolding
Author
A. M. Jacobson
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2154-0

Other articles of this Issue 7/2011

Diabetologia 7/2011 Go to the issue

Article

Altered gene expression and spongiotrophoblast differentiation in placenta from a mouse model of diabetes in pregnancy

Article

Permanent diabetes during the first year of life: multiple gene screening in 54 patients

Article

Synaptotagmin-7 as a positive regulator of glucose-induced glucagon-like peptide-1 secretion in mice

Article

The effects of the Chinese medicine ZiBu PiYin recipe on the hippocampus in a rat model of diabetes-associated cognitive decline: a proteomic analysis

Article

Electroacupuncture counteracts the development of thermal hyperalgesia and the alteration of nerve growth factor and sensory neuromodulators induced by streptozotocin in adult rats

Article

AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits